RedHill Biopharma Ltd - Company Profile (NASDAQ:RDHL)

About RedHill Biopharma Ltd - (NASDAQ:RDHL)

RedHill Biopharma Ltd - logoRedHill Biopharma Ltd. is a biopharmaceutical company. The Company is focused on the development and commercialization of clinical-stage, orally-administered, small molecule drugs for the treatment of gastrointestinal (GI) and inflammatory diseases and cancer. Its seven clinical-stage therapeutic candidates include RHB-105, RHB-104, BEKINDA, RHB-106, YELIVA, MESUPRON and RIZAPORT and related research and development programs. RHB-105 is intended for the eradication of H. pylori bacterial infection in the GI tract. BEKINDA is under development for the intended use in the indications, such as acute gastroenteritis and gastritis and irritable bowel syndrome with diarrhea (IBS-D). RIZAPORT is an oral thin film formulation of rizatriptan intended for the treatment of acute migraine headaches. MESUPRON is a protease inhibitor administered by oral capsule. YELIVA is an orally-administered SK2 selective inhibitor with anti-inflammatory and anti-cancer activities.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RDHL
  • CUSIP: N/A
  • Web: www.redhillbio.com
Capitalization:
  • Market Cap: $167.52 million
  • Outstanding Shares: 17,007,000
Average Prices:
  • 50 Day Moving Avg: $9.95
  • 200 Day Moving Avg: $10.29
  • 52 Week Range: $8.77 - $16.54
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -26.62
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $101,000.00
  • Price / Sales: 1,658.60
  • Book Value: $3.47 per share
  • Price / Book: 2.84
Profitability:
  • EBIDTA: ($34,690,000.00)
  • Return on Equity: -53.96%
  • Return on Assets: -47.25%
Debt:
  • Current Ratio: 5.84%
  • Quick Ratio: 5.84%
Misc:
  • Average Volume: 57,452 shs.
  • Beta: 0.56
  • Short Ratio: 2.31
 

Frequently Asked Questions for RedHill Biopharma Ltd - (NASDAQ:RDHL)

What is RedHill Biopharma Ltd -'s stock symbol?

RedHill Biopharma Ltd - trades on the NASDAQ under the ticker symbol "RDHL."

How were RedHill Biopharma Ltd -'s earnings last quarter?

RedHill Biopharma Ltd - (NASDAQ:RDHL) announced its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.64) by $0.14. View RedHill Biopharma Ltd -'s Earnings History.

Where is RedHill Biopharma Ltd -'s stock going? Where will RedHill Biopharma Ltd -'s stock price be in 2017?

3 equities research analysts have issued twelve-month price targets for RedHill Biopharma Ltd -'s stock. Their predictions range from $25.00 to $33.00. On average, they anticipate RedHill Biopharma Ltd -'s stock price to reach $28.00 in the next year. View Analyst Ratings for RedHill Biopharma Ltd -.

What are analysts saying about RedHill Biopharma Ltd - stock?

Here are some recent quotes from research analysts about RedHill Biopharma Ltd - stock:

  • 1. FBR & Co analysts commented, "RedHill Biopharma reported 4Q16 results that showed the company strongly positioned to achieve its objectives in 2017. Specifically, we think positive results from multiple clinical programs position RedHill to achieve value inflection points, including a top-line readout from the GUARD Phase III study with Bekinda in gastroenteritis, a second independent DSMB meeting for the MAP US Phase III study with RHB-104 in Crohn's disease (CD), and initiation of a confirmatory Phase III study with RHB-105 for H. pylori infection, which are all expected in 2Q17. While the balance sheet strengthened in 1Q17 (pro forma $66M in cash, no debt), the public offering completed in December 2016 was dilutive. Thus, we adjusted our price target from $36 to $25 to reflect the dilution as well as an adjustment in our projected timing for RHB-104 approval in CD to YE18. We continue to look for these milestones to be catalysts for the stock and reiterate our Outperform rating." (2/24/2017)
  • 2. According to Zacks Investment Research, "RedHill Biopharma focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases, including cancer. RedHill's proprietary pipeline includes: RHB-105 - a combination therapy for H.pylori infection; RHB-104 - a combination therapy for Crohn's disease and multiple sclerosis; BEKINDA - a once-daily oral formulation of ondansetron for acute gastroenteritis and IBS-D; RHB-106 - an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals; YELIVA - an orally-administered first-in-class SK2 selective inhibitor targeting oncology, inflammatory and gastrointestinal indications; MESUPRON - a uPA inhibitor targeting gastrointestinal and other solid tumors; RP101 - currently subject to an option-to-acquire, Hsp27 inhibitor targeting gastrointestinal cancers; RIZAPORT - an oral thin film formulation of rizatriptan for acute migraines. " (2/9/2017)

Who are some of RedHill Biopharma Ltd -'s key competitors?

Who owns RedHill Biopharma Ltd - stock?

RedHill Biopharma Ltd -'s stock is owned by many different of institutional and retail investors. Top institutional shareholders include Menora Mivtachim Holdings LTD. (2.47%), Bank Hapoalim BM (1.06%), Sabby Management LLC (0.64%), Candriam Luxembourg S.C.A. (0.42%), Renaissance Technologies LLC (0.36%) and Ingalls & Snyder LLC (0.24%). View Institutional Ownership Trends for RedHill Biopharma Ltd -.

Who sold RedHill Biopharma Ltd - stock? Who is selling RedHill Biopharma Ltd - stock?

RedHill Biopharma Ltd -'s stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC and Bank Hapoalim BM. View Insider Buying and Selling for RedHill Biopharma Ltd -.

Who bought RedHill Biopharma Ltd - stock? Who is buying RedHill Biopharma Ltd - stock?

RedHill Biopharma Ltd -'s stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jane Street Group LLC, Family Management Corp, Bank of New York Mellon Corp, Penserra Capital Management LLC and Oppenheimer & Co. Inc.. View Insider Buying and Selling for RedHill Biopharma Ltd -.

How do I buy RedHill Biopharma Ltd - stock?

Shares of RedHill Biopharma Ltd - can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of RedHill Biopharma Ltd - stock cost?

One share of RedHill Biopharma Ltd - stock can currently be purchased for approximately $9.85.

Analyst Ratings

Consensus Ratings for RedHill Biopharma Ltd - (NASDAQ:RDHL) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.00 (184.26% upside)

Analysts' Ratings History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/4/2017Roth CapitalSet Price TargetBuy$26.00LowView Rating Details
5/4/2017HC WainwrightSet Price TargetBuy$33.00LowView Rating Details
4/5/2017FBR & CoReiterated RatingBuyLowView Rating Details
3/29/2016NomuraReiterated RatingBuyN/AView Rating Details
11/11/2015Ascendiant Capital MarketsLower Price TargetBuy$28.00 -> $26.00N/AView Rating Details
9/29/2015Northland SecuritiesInitiated CoverageBuy$25.00N/AView Rating Details
7/2/2015MLV & Co.Initiated CoverageBuy$33.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
Earnings by Quarter for RedHill Biopharma Ltd - (NASDAQ:RDHL)
Earnings History by Quarter for RedHill Biopharma Ltd - (NASDAQ:RDHL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/20173/31/2017($0.64)($0.50)ViewN/AView Earnings Details
7/27/2016Q116($0.58)($0.06)ViewListenView Earnings Details
2/25/2016Q1($0.48)$0.04$0.05 millionViewListenView Earnings Details
11/9/2015Q315($0.51)($0.04)ViewN/AView Earnings Details
7/29/2015Q215($0.49)($0.07)ViewListenView Earnings Details
4/30/2015Q115($0.56)($0.50)ViewN/AView Earnings Details
2/26/2015Q414($0.60)$0.06ViewN/AView Earnings Details
11/10/2014($0.61)($0.50)ViewN/AView Earnings Details
7/24/2014($0.38)($0.52)ViewN/AView Earnings Details
6/6/2014($0.44)$0.39ViewN/AView Earnings Details
4/30/2014($0.44)$0.39$7.01 millionViewN/AView Earnings Details
11/12/2013Q3 13($0.62)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for RedHill Biopharma Ltd - (NASDAQ:RDHL)
2017 EPS Consensus Estimate: ($0.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.51)($0.51)($0.51)
Q3 20171($0.51)($0.51)($0.51)
Q4 20171$0.79$0.79$0.79
(Data provided by Zacks Investment Research)

Dividends

Dividend History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for RedHill Biopharma Ltd - (NASDAQ:RDHL)
Latest Headlines for RedHill Biopharma Ltd - (NASDAQ:RDHL)
Source:
DateHeadline
americanbankingnews.com logoQ2 2017 EPS Estimates for RedHill Biopharma Ltd - Raised by FBR & Co (RDHL)
www.americanbankingnews.com - May 8 at 7:41 AM
americanbankingnews.com logoHC Wainwright Analysts Give RedHill Biopharma Ltd - (RDHL) a $33.00 Price Target
www.americanbankingnews.com - May 7 at 7:44 AM
americanbankingnews.com logoRoth Capital Analysts Give RedHill Biopharma Ltd - (RDHL) a $26.00 Price Target
www.americanbankingnews.com - May 7 at 7:44 AM
americanbankingnews.com logoRedHill Biopharma Ltd - (RDHL) Issues Quarterly Earnings Results, Beats Expectations By $0.14 EPS
www.americanbankingnews.com - May 5 at 11:53 PM
americanbankingnews.com logoRedHill Biopharma Ltd - (RDHL) Receives Daily News Impact Score of 0.31
www.americanbankingnews.com - May 5 at 10:35 PM
americanbankingnews.com logoRedHill Biopharma Ltd - (RDHL) to Post FY2019 Earnings of $3.16 Per Share, FBR & Co Forecasts
www.americanbankingnews.com - May 5 at 7:58 PM
finance.yahoo.com logoRedHill Biopharma Announces Poster Presentation of the Positive RHB-105 Phase III Results for H. pylori Infection at Digestive Disease Week 2017
finance.yahoo.com - May 4 at 8:38 AM
americanbankingnews.com logoRedHill Biopharma Ltd - (RDHL) Receives Daily Media Impact Score of -0.12
www.americanbankingnews.com - May 2 at 5:28 PM
americanbankingnews.com logoZacks: Analysts Expect RedHill Biopharma Ltd - (RDHL) to Announce -$0.64 EPS
www.americanbankingnews.com - April 28 at 6:06 PM
americanbankingnews.com logoRedHill Biopharma Ltd - (RDHL) Getting Positive News Coverage, Study Finds
www.americanbankingnews.com - April 28 at 12:44 AM
seekingalpha.com logoRedhill Biopharma (RDHL) R&D Day on BEKINDA (Acute Gastroenteritis and IBS-D) - Slideshow
seekingalpha.com - April 27 at 7:54 PM
finance.yahoo.com logoRedHill Biopharma to Host First Quarter 2017 Financial Results Conference Call on May 3, 2017
finance.yahoo.com - April 25 at 10:16 AM
streetinsider.com logoRedHill Biopharma (RDHL) Enrolls Last Patient in the BEKINDA Phase II Study for IBS-D
www.streetinsider.com - April 24 at 11:53 AM
finance.yahoo.com logoRedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D
finance.yahoo.com - April 24 at 11:53 AM
finance.yahoo.com logoRedHill Biopharma Announces Peer-Reviewed Publication of the Positive YELIVA® Phase I Study Results in Advanced Solid Tumors
finance.yahoo.com - April 20 at 8:38 AM
finance.yahoo.com logoRedHill Biopharma to Host R&D Day on BEKINDA® for Acute Gastroenteritis and IBS-D
finance.yahoo.com - April 19 at 9:37 AM
finance.yahoo.com logoRedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA® - Yahoo Finance
finance.yahoo.com - April 18 at 9:32 AM
finance.yahoo.com logoRedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA®
finance.yahoo.com - April 18 at 9:32 AM
streetinsider.com logoRedHill Biopharma (RDHL) & IntelGenx Awarded Marketing Approval of RIZAPORT® for Migraines in Luxembourg - StreetInsider.com
www.streetinsider.com - April 15 at 8:34 AM
finance.yahoo.com logoRedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT® for Migraines in Luxembourg
finance.yahoo.com - April 13 at 9:46 AM
finance.yahoo.com logoRedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam®
finance.yahoo.com - April 7 at 7:51 PM
americanbankingnews.com logo Analysts Expect RedHill Biopharma Ltd - (RDHL) Will Announce Earnings of -$0.64 Per Share
www.americanbankingnews.com - April 7 at 6:51 PM
streetinsider.com logoRedHill Biopharma (RDHL) Secures Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam® - StreetInsider.com
www.streetinsider.com - April 7 at 12:12 PM
americanbankingnews.com logoRedHill Biopharma Ltd -'s (RDHL) "Buy" Rating Reiterated at FBR & Co
www.americanbankingnews.com - April 5 at 9:12 PM
finance.yahoo.com logoRedHill Biopharma to Present at the 2017 MAP Conference
finance.yahoo.com - March 22 at 7:42 AM
finance.yahoo.com logoRedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease
finance.yahoo.com - March 21 at 10:38 AM
finance.yahoo.com logoRedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn's Disease
finance.yahoo.com - March 21 at 10:38 AM
seekingalpha.com logoRedHill Biopharma: Multiple Drugs In Advanced Phase III Development Provide Substantial Upside
seekingalpha.com - March 20 at 5:32 PM
globenewswire.com logoRedHill Biopharma to Present at the BIO-Europe Spring 2017 Conference - GlobeNewswire (press release)
globenewswire.com - March 15 at 7:43 PM
finance.yahoo.com logoRedHill Biopharma to Present at the BIO-Europe Spring 2017 Conference
finance.yahoo.com - March 13 at 9:33 AM
seekingalpha.com logo2 Must-Have Biotechs For The Approaching 2nd Quarter
seekingalpha.com - March 9 at 7:30 PM
us.rd.yahoo.com logoRedHill Biopharma’s Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating to Donnatal®
us.rd.yahoo.com - March 7 at 9:30 AM
finance.yahoo.com logoREDHILL BIOPHARMA LTD. Financials
finance.yahoo.com - March 1 at 7:42 PM
streetinsider.com logoRedhill Biopharma (RDHL) PT Lowered to $25 at FBR Capital Citing Dilutive Dec '16 Public Offering; 4Q Results Positive - StreetInsider.com
www.streetinsider.com - February 24 at 8:11 AM
globenewswire.com logoRedHill Biopharma Announces Availability of Its Annual Report on Form 20-F Through Its Website - GlobeNewswire (press release)
globenewswire.com - February 24 at 12:36 AM
finance.yahoo.com logoRedHill Biopharma Announces Availability of Its Annual Report on Form 20-F Through Its Website
finance.yahoo.com - February 23 at 7:35 PM
finance.yahoo.com logoRedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results
finance.yahoo.com - February 23 at 8:32 AM
streetinsider.com logoRedHill Biopharma (RDHL) Treats Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis - StreetInsider.com
www.streetinsider.com - February 23 at 12:39 AM
nasdaq.com logoAPOP Pops On Study Data, EYEG Catches Investors' Eyes, CDTX Loses Radiance
www.nasdaq.com - February 22 at 9:31 AM
streetinsider.com logoRedHill Biopharma (RDHL) Treats Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis
www.streetinsider.com - February 21 at 5:23 PM
us.rd.yahoo.com logoRedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
us.rd.yahoo.com - February 21 at 5:23 PM
globenewswire.com logoRedHill Biopharma to Host Fourth Quarter and Full-Year 2016 Financial Results Conference Call on February 23, 2017 - GlobeNewswire (press release)
globenewswire.com - February 18 at 8:13 AM
finance.yahoo.com logoRedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
finance.yahoo.com - February 13 at 8:52 AM
finance.yahoo.com logo4 Drug Stocks that are Broker Favorites
finance.yahoo.com - February 7 at 8:31 AM
finance.yahoo.com logoRedHill Biopharma to Present at the BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 8:49 AM
us.rd.yahoo.com logo6:03 am RedHill Biopharma provides an update on key programs, potential milestones and estimated timelines
us.rd.yahoo.com - January 12 at 8:09 PM
streetinsider.com logoRedHill Biopharma (RDHL) Begins Dosing in PK Study with RHB-105 for H. pylori Infection - StreetInsider.com
www.streetinsider.com - January 12 at 1:12 AM
streetinsider.com logoRedHill Biopharma (RDHL) Says RHB-104 Granted Qualified Infectious Disease Product (QIDP) from FDA - StreetInsider.com
www.streetinsider.com - January 12 at 1:12 AM
us.rd.yahoo.com logoRedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections
us.rd.yahoo.com - January 11 at 8:11 PM
streetinsider.com logoRedHill Biopharma (RDHL) Begins Dosing in PK Study with RHB-105 for H. pylori Infection
www.streetinsider.com - January 10 at 9:12 PM

Social

Chart

RedHill Biopharma Ltd - (RDHL) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff